Palifermin
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Toxic Epidermal Necrolysis
Conditions
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Trial Timeline
Oct 1, 2010 → Dec 1, 2014
NCT ID
NCT02037347About Palifermin
Palifermin is a phase 1/2 stage product being developed by Swedish Orphan Biovitrum for Toxic Epidermal Necrolysis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02037347. Target conditions include Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02037347 | Phase 1/2 | Terminated |
Competing Products
13 competing products in Toxic Epidermal Necrolysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TURALIO™ | Daiichi Sankyo | Pre-clinical | 23 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| Saquinavir | Roche | Phase 2 | 52 |
| Doxycycline 50Mg Tablet | Amgen | Phase 2 | 51 |
| HPN-100 + HPN-100 or Placebo + Placebo + Moxifloxacin + HPN-100 + HPN-100 | Amgen | Phase 1 | 32 |
| Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha | Bristol Myers Squibb | Phase 1/2 | 40 |
| Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated) | Sanofi | Pre-clinical | 22 |
| Butenafine HCl 1% (BAY1896425) | Bayer | Phase 3 | 74 |
| ClinOleic (Baxter Healthcare, Deerfield, IL, USA) | Baxter | Phase 1 | 30 |
| SENS-401 (R-Azasetron Besylate) | Sensorion | Phase 2 | 44 |
| TNX-1300 | Tonix Pharmaceuticals | Phase 2 | 44 |
| ADX-629 + Placebo | Aldeyra Therapeutics | Phase 1/2 | 33 |
| Ryanodex (dantrolene sodium) for injectable suspension | Eagle Pharmaceuticals | Phase 2 | 44 |